{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:17:41Z","timestamp":1792185461307,"version":"4.4.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008227","name":"University of South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["SRUG2204203861"],"award-info":[{"award-number":["SRUG2204203861"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.118018","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T13:29:45Z","timestamp":1754314185000},"page":"118018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Examining the 2-aryl-5-nitrobenzofuran-based hydrazones for anti-breast (MCF-7) cancer activity, potential to induce cell cycle arrest and inhibit receptor tyrosine kinases (VEGFR-2 &amp; EGFR)"],"prefix":"10.1016","volume":"298","author":[{"given":"Jackson K.","family":"Nkoana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garland K.","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Elhenawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6018-5671","authenticated-orcid":false,"given":"Malose J.","family":"Mphahlele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118018_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1078191","article-title":"Trend of disease burden and risk factors of breast cancer in developing countries and territories, from 1990 to 2019: results from the global burden of disease study 2019","volume":"10","author":"Lv","year":"2023","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ejmech.2025.118018_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116472","article-title":"Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions","volume":"272","author":"Thakur","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106425","article-title":"Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy","volume":"133","author":"Liu","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128258","article-title":"Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives","volume":"48","author":"Ahmed","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118018_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107278","article-title":"Recent development of VEGFR small molecule inhibitors as anticancer agents: a patent review (2021\u20132023)","volume":"146","author":"Zeng","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib6","doi-asserted-by":"crossref","DOI":"10.1039\/D4RA05244G","article-title":"Recent updates on potential of VEGFR-2 small molecule inhibitors as anticancer agents","volume":"14","author":"Chaudhari","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.118018_bib7","doi-asserted-by":"crossref","first-page":"102988","DOI":"10.1016\/j.bioorg.2019.102988","article-title":"3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR2 inhibitors: design, synthesis and biological evaluation","volume":"89","author":"Sobhy","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2019.100009","article-title":"Vascular endothelial growth factor receptor (VEGFR-2)\/KDR inhibitors: medicinal chemistry perspective","volume":"2","author":"Modi","year":"2019","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118018_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jb\/mvs136","article-title":"Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases","volume":"153","author":"Shibuya","year":"2013","journal-title":"J. Biochem."},{"key":"10.1016\/j.ejmech.2025.118018_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14534","article-title":"Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy","volume":"103","author":"Budipramana","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2025.118018_bib11","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-24-0281","volume":"30","author":"Fusco","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118018_bib12","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.3390\/molecules26216677","article-title":"Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism","volume":"26","author":"Abourehab","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118018_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113963","article-title":"Dual target inhibitors based on EGFR: promising anticancer agents for the treatment of cancers (2017-)","volume":"227","author":"Hu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ejmech.2014.11.039","article-title":"Bioactive benzofuran derivatives: a review","volume":"97","author":"Khanan","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ejmech.2014.11.047","article-title":"Bioactive benzofuran derivatives: Moraceae A\u2013Z in medicinal chemistry","volume":"90","author":"Naik","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib16","doi-asserted-by":"crossref","first-page":"11096","DOI":"10.1039\/D3RA01383A","article-title":"Anticancer therapeutic potential of benzofuran scaffolds","volume":"13","author":"Abbas","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.118018_bib17","first-page":"193","article-title":"Review of biological activities of hydrazones","volume":"23","author":"Ali","year":"2012","journal-title":"Indones. J. Pharm."},{"key":"10.1016\/j.ejmech.2025.118018_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/antibiotics11020191","article-title":"A review on the antimicrobial activity of schiff bases: data collection and recent studies","volume":"11","author":"Ceramella","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejmech.2025.118018_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.30574\/gscbps.2022.21.3.0484","article-title":"Biological applications of schiff bases: an overview","volume":"21","author":"Raju","year":"2022","journal-title":"GSC Biol. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2025.118018_bib20","first-page":"1","article-title":"Review on azomethine-compounds with their applications","volume":"7","author":"Aljamali","year":"2021","journal-title":"Int. J. Chem. Synth. Chem React."},{"key":"10.1016\/j.ejmech.2025.118018_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105092","article-title":"An update on derivatisation and repurposing of clinical nitrofuran drugs","volume":"140","author":"Zuma","year":"2019","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2025.118018_bib22","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/ph16070938","article-title":"Pharmacological activities of schiff bases and their derivatives with low and high molecular phosphonates","volume":"16","author":"Tsacheva","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118018_bib23","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3390\/molecules23061318","article-title":"Design, synthesis, and evaluation of a new series of hydrazones as small-molecule akt inhibitors for NSCLC therapy","volume":"23","author":"Erd\u00f6nmez","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118018_bib24","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.3390\/molecules27196203","article-title":"Discovery of new VEGFR-2 inhibitors: design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies","volume":"27","author":"Elkaeed","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118018_bib25","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1134\/S1070363217090183","article-title":"Synthesis of hydrazone derivatives of benzofuran and their antibacterial and antifungal activity","volume":"87","author":"Subhashinia","year":"2017","journal-title":"Russ. J. Gen. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.128318","article-title":"An efficient synthesis, structural (SC-XRD) and spectroscopic (FTIR, 1HNMR, MS spectroscopic) characterization of novel benzofuran-based hydrazones: An exaerimental and theoretical studies","volume":"1216","author":"Khalid","year":"2020","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118018_bib27","first-page":"118","article-title":"Benzofuran hydrazones as potential scaffold in the development of multifunctional drugs: synthesis and evaluation of antioxidant, photoprotective and antiproliferative activity","volume":"156","author":"Baldisserotto","year":"2018","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118018_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.136284","article-title":"Design, synthesis, biological evaluation, and molecular docking of euparin and 2-hydroxy acetophenone hydrazone derivatives as potential AChE inhibitors","volume":"1293","author":"Zarrinzadeh","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118018_bib29","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.3390\/molecules26247435","article-title":"Synthesis, structural characterization, and in vitro and in silico antifungal evaluation of azo-azomethine pyrazoles (PhN2(PhOH)CHN(C3N2 (CH3)3)PhR, R = H or NO2)","volume":"26","author":"Fernandez","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118018_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142326","article-title":"EGFR inhibitors across generations: progress, challenges, and future directions","volume":"1339","author":"Deshmukh","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118018_bib31","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1021\/acschembio.8b00225","article-title":"The nitro group as a masked electrophile in covalent enzyme inhibition","volume":"13","author":"Ray","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118018_bib32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3390\/ph15060717","article-title":"The diverse biological activity of recently synthesized nitro compounds","volume":"15","author":"Noriega","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118018_bib33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.ejmech.2025.118018_bib34","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.3390\/molecules29153475","article-title":"Recent advances in the application of nitro(het)aromatic compounds for treating and\/or fluorescent imaging of tumor hypoxia","volume":"29","author":"Anichina","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118018_bib35","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1007\/s11696-023-02804-5","article-title":"Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs","volume":"77","author":"Chandra","year":"2023","journal-title":"Chem. Pap."},{"key":"10.1016\/j.ejmech.2025.118018_bib36","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1186\/s40064-016-2996-5","article-title":"Halogen-directed drug design for Alzheimer's disease: a combined density functional and molecular docking study","volume":"5","author":"Rahman","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1016\/j.ejmech.2025.118018_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108465","article-title":"Synthesis and profiling (in vitro and in silico) of the 6-methoxy\/hydroxy substituted 7-acetyl-2-aryl-5-bromobenzofurans for antihyperglycemic, cytotoxic and antioxidant properties","volume":"161","author":"Ajiboye","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2021.105990","article-title":"Biological evaluation of antiproliferative and anti-invasive properties of an androstadiene derivative on human cervical cancer cell lines","volume":"214","author":"Kulm\u00e1ny","year":"2021","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118018_bib39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0022-1759(00)00233-7","article-title":"Flow cytometry of apoptotic cell death","volume":"243","author":"Vermes","year":"2000","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ejmech.2025.118018_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-38264-w","article-title":"New proapoptotic chemotherapeutic agents based on the quinolone-3-carboxamide scaffold acting by VEGFR-2 inhibition","volume":"13","author":"El-Fakharany","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118018_bib41","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1021\/acs.jctc.1c00810","article-title":"Efficient exploration of chemical space with docking and deep learning","volume":"17","author":"Yang","year":"2021","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2025.118018_bib42","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/jcc.24829","article-title":"CHARMM-GUI ligand reader and modeler for CHARMM force field generation of small molecules","volume":"38","author":"Kim","year":"2017","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib43","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1021\/acs.jctc.3c00714","article-title":"Efficient empirical valence bond simulations with GROMACS","volume":"19","author":"Oanca","year":"2023","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2025.118018_bib44","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/molecules28020536","article-title":"Revealing the reasons for degeneration of resonance-assisted hydrogen bond on the aromatic platform: calculations of ortho-, meta-, para-disubstituted benzenes, and (Z)-(E)-olefins","volume":"28","author":"Afonin","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118018_bib45","first-page":"o12","article-title":"Three dimensional aggregation in 2-hydroxy-3-iodo-5-nitrobenzaldehyde involving C\u2013H\u22efO, iodo\u2013nitro and aromatic \u03c0\u2013\u03c0 stacking interactions, and isolated dimers in disordered 2,4-diiodo-6-nitroanisole","volume":"C60","author":"Garden","year":"2004","journal-title":"Acta Crystallogr."},{"key":"10.1016\/j.ejmech.2025.118018_bib46","first-page":"150","article-title":"Contrasting the supramolecular structures in the isomeric pair 5-bromo-3-nitrosalicylaldehyde phenylhydrazone and 3-bromo-5-nitrosalicylaldehyde phenylhydrazone","volume":"C69","author":"Gomes","year":"2013","journal-title":"Acta Crystallogr."},{"key":"10.1016\/j.ejmech.2025.118018_bib47","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1021\/cr030083c","article-title":"Interrelation between H-bond and Pi-electron delocalization","volume":"105","author":"Sobczyk","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2025.118018_bib48","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/molecules22040552","article-title":"NMR and IR investigations of strong intramolecular hydrogen bonds","volume":"22","author":"Hansen","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118018_bib49","doi-asserted-by":"crossref","DOI":"10.1039\/D1RA08046F","article-title":"19F-centred NMR analysis of mono-fluorinated compounds","volume":"12","author":"Smith","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.118018_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138398","article-title":"Synthesis, structural characterization, and quantum chemical study of the 7-acetyl-5-nitrobenzofurans as anticancer agents with antioxidant properties","volume":"1311","author":"Maluleka","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118018_bib51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.molstruc.2016.05.064","article-title":"Microwave assisted regioselective synthesis and 2D-NMR studies of novel azoles and azoloazines utilizing fluorine-containing building blocks","volume":"1121","author":"Al-Bogami","year":"2016","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118018_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/ph11020054","article-title":"Multidirectional efficacy of biologically active nitro compounds included in medicines","volume":"11","author":"Olender","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118018_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119527","article-title":"A comprehensive review on time-tested anticancer drug doxorubicin","volume":"278","author":"Sritharan","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2025.118018_bib54","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1758834016630976","article-title":"Nintedanib in NSCLC: evidence to date and place in therapy","volume":"8","author":"Bronte","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ejmech.2025.118018_bib55","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.2147\/OTT.S78805","article-title":"Profile of nintedanib in the treatment of solid tumors: the evidence to date","volume":"8","author":"Awasthi","year":"2015","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2025.118018_bib56","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1016\/j.bmcl.2018.09.016","article-title":"Methyl-containing pharmaceuticals: methylation in drug design","volume":"28","author":"Suna","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118018_bib57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1134\/S1068162022010113","article-title":"Heterocyclic resveratrol analogs: synthesis and physiological activity. Part 2: analogs obtained by the replacement of ethylene fragments with heterocyclic residues","volume":"48","author":"Semenov","year":"2022","journal-title":"Russ. J. Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib58","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7324\/JAPS.2019.90717","article-title":"Resveratrol and pterostilbene: a comparative overview of their chemistry, biosynthesis, plant sources and pharmacological properties","volume":"9","author":"Chan","year":"2019","journal-title":"J. Appl. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2025.118018_bib59","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1126\/science.287.5460.1969","article-title":"Mechanism-based target identification and drug discovery in cancer research","volume":"287","author":"Gibbs","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118018_bib60","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00210-021-02078-2","article-title":"Genotoxic and cytotoxic effects of the drug dipyrone sodium in African green monkey kidney (Vero) cell line exposed in vitro","volume":"394","author":"Gomes","year":"2021","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejmech.2025.118018_bib61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0014-4827(02)00032-0","article-title":"Staurosporine-induced death of MCF-7 human breast cancer cells: a distinction between caspase-3-dependent steps of apoptosis and the critical lethal lesions","volume":"283","author":"Xue","year":"2003","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2025.118018_bib62","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","article-title":"The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer","volume":"36","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif."},{"key":"10.1016\/j.ejmech.2025.118018_bib63","doi-asserted-by":"crossref","first-page":"8600","DOI":"10.1007\/s12035-024-04130-7","article-title":"Uncovering cell cycle dysregulations and associated mechanisms in cancer and neurodegenerative disorders: a glimpse of hope for repurposed drugs","volume":"61","author":"Advani","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2025.118018_bib64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/molecules26010017","article-title":"Recent trends in enzyme inhibition and activation in drug design","volume":"26","author":"Geronikaki","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118018_bib65","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/DDDT.S344750","article-title":"New series of VEGFR-2 inhibitors and apoptosis enhancers: design, synthesis and biological evaluation","volume":"16","author":"Abdallah","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2025.118018_bib66","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1021\/ja301056a","article-title":"Halogen-enriched fragment libraries as leads for drug rescue of mutant p53","volume":"134","author":"Wilcken","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118018_bib67","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.3390\/pr10102054","article-title":"FDA-approved trifluoromethyl group-containing drugs: a review of 20 years","volume":"10","author":"Nair","year":"2022","journal-title":"Processes"},{"key":"10.1016\/j.ejmech.2025.118018_bib68","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1021\/acs.jmedchem.2c02015","article-title":"\u201cMagic chloro\u201d: profound effects of the chlorine atom in drug discovery","volume":"66","author":"Chiodi","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib69","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1526-4998(200001)56:1<3::AID-PS107>3.0.CO;2-P","article-title":"Influence of chlorine substituents on biological activity of chemicals: a review","volume":"56","author":"Naumann","year":"2000","journal-title":"Pest Manag. Sci."},{"key":"10.1016\/j.ejmech.2025.118018_bib70","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ps.1829","article-title":"The unique role of halogen substituents in the design of modern agrochemicals","author":"Jeschke","year":"2010","journal-title":"Pest Manag. Sci."},{"key":"10.1016\/j.ejmech.2025.118018_bib71","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/14756366.2018.1460824","article-title":"Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl) benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer","volume":"33","author":"Xie","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116415","article-title":"Discovery of N-(4-((6-(3,5- dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors","volume":"271","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib73","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118018_bib74","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejphar.2008.10.024","article-title":"An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells","volume":"600","author":"Chang","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118018_bib75","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000509670","article-title":"Synergistic inhibition of renal fibrosis by nintedanib and gefitinib in a murine model of obstructive nephropathy","volume":"7","author":"Feng","year":"2021","journal-title":"Kidney Dis."},{"key":"10.1016\/j.ejmech.2025.118018_bib76","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"Pros. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2025.118018_bib77","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/BJ20121513","article-title":"Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain","volume":"448","author":"Park","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2025.118018_bib78","doi-asserted-by":"crossref","first-page":"14073","DOI":"10.1021\/ja063076p","article-title":"Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides","volume":"128","author":"Rezai","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118018_bib79","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1021\/jm3012068","article-title":"Principles and applications of halogen bonding in medicinal chemistry and chemical biology","volume":"56","author":"Wilcken","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib80","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/jm980551o","article-title":"Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones","volume":"42","author":"Traxler","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118018_bib81","first-page":"2063","article-title":"SwissADME predictions of pharmacokinetics and drug-likeness properties of small molecules present in Ipomoea mauritiana Jacq","volume":"8","author":"Ranjith","year":"2019","journal-title":"J. Pharmacogn. Phytochem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:08:24Z","timestamp":1777529304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425007834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":81,"alternative-id":["S0223523425007834"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118018","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Examining the 2-aryl-5-nitrobenzofuran-based hydrazones for anti-breast (MCF-7) cancer activity, potential to induce cell cycle arrest and inhibit receptor tyrosine kinases (VEGFR-2 & EGFR)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118018"}}